Suppr超能文献

COVID-19 患者接受氧疗时经验性抗生素治疗的临床影响。

Clinical Impact of Empirical Antibiotic Therapy in Patients With Coronavirus Disease 2019 Requiring Oxygen Therapy.

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

出版信息

J Korean Med Sci. 2022 Jul 25;37(29):e238. doi: 10.3346/jkms.2022.37.e238.

Abstract

Despite the low prevalence of secondary bacterial infection in coronavirus disease 2019 (COVID-19) patients, most of them were administered antibiotic therapy empirically. However, the prognostic impact of empirical antibiotic therapy has not been evaluated. We conducted retrospective propensity score-matched case-control study of 233 COVID-19 patients with moderate to severe illnesses who required oxygen therapy and evaluated whether empirical antibiotic therapy could improve clinical outcomes. Empirical antibiotic therapy did not improve clinical outcomes including length of stay, days with oxygen requirement, the proportion of patients with increased oxygen demand, the proportion of patients who required mechanical ventilation, and overall mortality. This finding implies that routine administration of antibiotics for the treatment of COVID-19 is not essential and should be restricted.

摘要

尽管在 2019 冠状病毒病(COVID-19)患者中,继发细菌感染的患病率较低,但大多数患者仍接受经验性抗生素治疗。然而,经验性抗生素治疗的预后影响尚未得到评估。我们对 233 名需要氧疗的中重度 COVID-19 患者进行了回顾性倾向评分匹配的病例对照研究,评估了经验性抗生素治疗是否能改善临床结局。经验性抗生素治疗并未改善临床结局,包括住院时间、需要吸氧的天数、需要增加吸氧需求的患者比例、需要机械通气的患者比例以及总体死亡率。这一发现表明,常规使用抗生素治疗 COVID-19 并非必要,应加以限制。

相似文献

4
Evaluation of early antibiotic use in patients with non-severe COVID-19 without bacterial infection.
Int J Antimicrob Agents. 2022 Jan;59(1):106462. doi: 10.1016/j.ijantimicag.2021.106462. Epub 2021 Oct 23.
7
Bacterial Co-Infection and Empirical Antibacterial Therapy in Patients With COVID-19.
J Korean Med Sci. 2023 Jan 30;38(4):e37. doi: 10.3346/jkms.2023.38.e37.
9
Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis.
Clin Microbiol Infect. 2021 Apr;27(4):520-531. doi: 10.1016/j.cmi.2020.12.018. Epub 2021 Jan 5.

引用本文的文献

4
Bacterial Co-Infection and Empirical Antibacterial Therapy in Patients With COVID-19.
J Korean Med Sci. 2023 Jan 30;38(4):e37. doi: 10.3346/jkms.2023.38.e37.
5
To Prescribe, or Not to Prescribe, That Is the Question.
J Korean Med Sci. 2022 Jul 25;37(29):e240. doi: 10.3346/jkms.2022.37.e240.

本文引用的文献

1
ESCMID COVID-19 living guidelines: drug treatment and clinical management.
Clin Microbiol Infect. 2022 Feb;28(2):222-238. doi: 10.1016/j.cmi.2021.11.007. Epub 2021 Nov 22.
3
The Spectrum of Antibiotic Prescribing During COVID-19 Pandemic: A Systematic Literature Review.
Microb Drug Resist. 2021 Dec;27(12):1705-1725. doi: 10.1089/mdr.2020.0619. Epub 2021 Jun 1.
4
Repurposing of antibiotics for clinical management of COVID-19: a narrative review.
Ann Clin Microbiol Antimicrob. 2021 May 21;20(1):37. doi: 10.1186/s12941-021-00444-9.
6
A call for antimicrobial stewardship in patients with COVID-19: a nationwide cohort study in Korea.
Clin Microbiol Infect. 2021 Apr;27(4):653-655. doi: 10.1016/j.cmi.2020.10.024. Epub 2020 Oct 31.
7
Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline.
Clin Microbiol Infect. 2021 Jan;27(1):61-66. doi: 10.1016/j.cmi.2020.09.041. Epub 2020 Oct 1.
8
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016. Epub 2020 Jul 22.
9
Co-infections in people with COVID-19: a systematic review and meta-analysis.
J Infect. 2020 Aug;81(2):266-275. doi: 10.1016/j.jinf.2020.05.046. Epub 2020 May 27.
10
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验